ArticleFrontiers in immunology2018
Serum Levels of Migration Inhibitory Factor (MIF) and
Marco Alonso Martinez-Guzman, Anabell Alvarado-Navarro, Vidal Delgado-Rizo, Alejandra Garcia-Orozco, Jorge Arturo Mayorga-Rodríguez, Ana Laura Pereira-Suarez, Mary Fafutis-Morris
Open access · goldAbstract read
In one paragraphArticle in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 2 institutions in 1 country.
Marco Alonso Martinez-GuzmanDoctorado en Ciencias Biomédicas con Orientación en Inmunología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
Anabell Alvarado-NavarroCentro de Investigación en Inmunología y Dermatología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
Vidal Delgado-RizoLaboratorio de Inmunología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
Alejandra Garcia-OrozcoDoctorado en Ciencias Biomédicas con Orientación en Inmunología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
Jorge Arturo Mayorga-RodríguezLaboratorio de Micología, Instituto Dermatológico de Jalisco "Dr. José Barba Rubio", Zapopan, Mexico.
Ana Laura Pereira-SuarezLaboratorio de Inmunología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
Mary Fafutis-MorrisCentro de Investigación en Inmunología y Dermatología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico.
Universidad de Guadalajara · MXSecretaría de Salud de Jalisco · MX
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Leprosy is a chronic disease caused by
Indexed as
AdultAntigens, Differentiation, B-LymphocyteBiopsyCase-Control StudiesFemaleHealthy VolunteersHistocompatibility Antigens Class IIHost Microbial InteractionsHumansImmunity, CellularIntramolecular OxidoreductasesLeprosy, LepromatousMacrophage Migration-Inhibitory FactorsMaleMiddle AgedMycobacterium lepraeAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIIntramolecular Oxidoreductasesinvariant chainMacrophage Migration-Inhibitory FactorsMIF protein, humanCD74lepromatous leprosyleprosymigration inhibitory factorserum cytokinesskin
Identifiers
PMID29487601
PMCPMC5816948
OpenAlexW2794362412
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390